Increased expression of ZBP-89 and its prognostic significance in hepatocellular carcinoma

Histopathology

Volumn 60, Issue 7, 2012, Pages 1114-1124

  Zhang, Chris Z Y ^a   Cao, Yun ^b   Yun, Jing Ping ^b   Chen, George G ^a   Lai, Paul B S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Hepatocellular carcinoma; Immunohistochemistry; Prognosis; ZBP 89

Indexed keywords

MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG; ZBP 89; ZINC FINGER PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CELLULAR DISTRIBUTION; COLONY FORMING CELL; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL CARCINOMA; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WORLD HEALTH ORGANIZATION;

ADULT; AGED; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA PRIMERS; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLY(ADP-RIBOSE) POLYMERASES; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELL ASSAY; UP-REGULATION;

HEPATITIS B VIRUS;

EID: 84862783937     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04136.x     Document Type: Article

References (42)

1. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004; 5; 215-219.
2. Worns MA, Weinmann A, Pfingst K et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J. Clin. Gastroenterol. 2009; 43; 489-495.
3. Braillon A. Hepatocellular carcinoma and evidence-based surgery. World J. Gastroenterol. 2009; 15; 5371.
4. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J. Clin. Oncol. 2005; 23; 2892-2899.
5. Liu AW, Cai J, Zhao XL et al. The clinicopathological significance of BUBR1 overexpression in hepatocellular carcinoma. J. Clin. Pathol. 2009; 62; 1003-1008.
6. Yun JP, Miao J, Chen GG et al. Increased expression of nucleophosmin/B23 in hepatocellular carcinoma and correlation with clinicopathological parameters. Br. J. Cancer 2007; 96; 477-484.
7. Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 2006; 25; 1125-1142.
8. Sicklick JK, Li YX, Jayaraman A et al. Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis 2006; 27; 748-757.
9. Zhang CZ, Chen GG, Lai PB. Transcription factor ZBP-89 in cancer growth and apoptosis. Biochim. Biophys. Acta 2010; 1806; 36-41.
10. Law GL, Itoh H, Law DJ, Mize GJ, Merchant JL, Morris DR. Transcription factor ZBP-89 regulates the activity of the ornithine decarboxylase promoter. J. Biol. Chem. 1998; 273; 19955-19964.
11. Wu Y, Zhang X, Salmon M, Zehner ZE. The zinc finger repressor, ZBP-89, recruits histone deacetylase 1 to repress vimentin gene expression. Genes Cells 2007; 12; 905-918.
12. Keates AC, Keates S, Kwon JH et al. ZBP-89, Sp1, and nuclear factor-kappa B regulate epithelial neutrophil-activating peptide-78 gene expression in Caco-2 human colonic epithelial cells. J. Biol. Chem. 2001; 276; 43713-43722.
13. Bai L, Merchant JL. Transcription factor ZBP-89 cooperates with histone acetyltransferase p300 during butyrate activation of p21waf1 transcription in human cells. J. Biol. Chem. 2000; 275; 30725-30733.
14. Vesely K, Jurajda M, Nenutil R, Vesela M. Expression of p53, cyclin D1 and EGFR correlates with histological grade of adult soft tissue sarcomas: a study on tissue microarrays. Neoplasma 2009; 56; 239-244.
15. Moran A, Iniesta P, de Juan C, García-Aranda C, Díaz-López A, Benito M. Impairment of stromelysin-1 transcriptional activity by promoter mutations in high microsatellite instability colorectal tumors. Cancer Res. 2005; 65; 3811-3814.
16. Frensing T, Kaltschmidt C, Schmitt-John T. Characterization of a neuregulin-1 gene promoter: positive regulation of type I isoforms by NF-kappaB. Biochim. Biophys. Acta 2008; 1779; 139-144.
17. Feng Y, Wang X, Xu L et al. The transcription factor ZBP-89 suppresses p16 expression through a histone modification mechanism to affect cell senescence. FEBS J. 2009; 276; 4197-4206.
18. Li X, Xiong JW, Shelley CS, Park H, Arnaout MA. The transcription factor ZBP-89 controls generation of the hematopoietic lineage in zebrafish and mouse embryonic stem cells. Development 2006; 133; 3641-3650.
19. Salmon M, Owens GK, Zehner ZE. Over-expression of the transcription factor, ZBP-89, leads to enhancement of the C2C12 myogenic program. Biochim. Biophys. Acta 2009; 1793; 1144-1155.
20. Chen GG, Merchant JL, Lai PB et al. Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89. Am. J. Pathol. 2003; 162; 1823-1829.
21. Xiao J, Zhang Z, Chen GG et al. Nucleophosmin/B23 interacts with p21WAF1/CIP1 and contributes to its stability. Cell Cycle 2009; 8; 889-895.
22. Park H, Shelley CS, Arnaout MA. The zinc finger transcription factor ZBP-89 is a repressor of the human beta 2-integrin CD11b gene. Blood 2003; 101; 894-902.
23. Bai L, Logsdon C, Merchant JL. Regulation of epithelial cell growth by ZBP-89: potential relevance in pancreatic cancer. Int. J. Gastrointest. Cancer 2002; 31; 79-88.
24. Bandres E, Malumbres R, Cubedo E et al. A gene signature of 8 genes could identify the risk of recurrence and progression in Dukes' B colon cancer patients. Oncol. Rep. 2007; 17; 1089-1094.
25. Bai L, Kao JY, Law DJ, Merchant JL. Recruitment of ataxia-telangiectasia mutated to the p21(waf1) promoter by ZBP-89 plays a role in mucosal protection. Gastroenterology 2006; 131; 841-852.
26. Bai L, Merchant JL. ATM phosphorylates ZBP-89 at Ser202 to potentiate p21waf1 induction by butyrate. Biochem. Biophys. Res. Commun. 2007; 359; 817-821.
27. Bai L, Yoon SO, King PD, Merchant JL. ZBP-89-induced apoptosis is p53-independent and requires JNK. Cell Death Differ. 2004; 11; 663-673.
28. Law DJ, Labut EM, Merchant JL. Intestinal overexpression of ZNF148 suppresses ApcMin/+ neoplasia. Mamm. Genome 2006; 17; 999-1004.
29. Woo AJ, Moran TB, Schindler YL et al. Identification of ZBP-89 as a novel GATA-1-associated transcription factor involved in megakaryocytic and erythroid development. Mol. Cell. Biol. 2008; 28; 2675-2689.
30. Taniuchi T, Mortensen ER, Ferguson A, Greenson J, Merchant JL. Overexpression of ZBP-89, a zinc finger DNA binding protein, in gastric cancer. Biochem. Biophys. Res. Commun. 1997; 233; 154-160.
31. Aoki T, Katsumata K, Tsuchida A, Tomioka H, Koyanagi Y. Correlation between malignancy grade and p53 gene in relation to thymidine phosphorylase activity in colorectal cancer patients. Oncol. Rep. 2002; 9; 1267-1271.
32. Zhang MF, Zhang ZY, Fu J, Yang YF, Yun JP. Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma. J. Transl. Med. 2009; 7; 110.
33. Yu J, Kane S, Wu J et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin. Cancer Res. 2009; 15; 3023-3028.
34. El-Shanawani FM, Abdel-Hadi AA, Abu Zikri NB, Ismail A, El-Ansary M, El-Raai A. Clinical significance of aflatoxin, mutant P53 gene and sIL-2 receptor in liver cirrhosis and hepatocellular carcinoma. J. Egypt. Soc. Parasitol. 2006; 36; 221-239.
35. Liu CJ, Kao JH. Hepatitis B virus-related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors. J. Chin. Med. Assoc. 2007; 70; 141-145.
36. Holley-Guthrie EA, Seaman WT, Bhende P, Merchant JL, Kenney SC. The Epstein-Barr virus protein BMRF1 activates gastrin transcription. J. Virol. 2005; 79; 745-755.
37. Datta S, Banerjee A, Chandra PK, Chakravarty R. Pin1-HBx interaction: a step toward understanding the significance of hepatitis B virus genotypes in hepatocarcinogenesis. Gastroenterology 2007; 133; 727-728; author reply 728-729.
38. Chen GG, Lai PB, Chan PK et al. Decreased expression of Bid in human hepatocellular carcinoma is related to hepatitis B virus X protein. Eur. J. Cancer 2001; 37; 1695-1702.
39. Bai L, Ni HM, Chen X, DiFrancesca D, Yin XM. Deletion of Bid impedes cell proliferation and hepatic carcinogenesis. Am. J. Pathol. 2005; 166; 1523-1532.
40. Law DJ, Labut EM, Adams RD, Merchant JL. An isoform of ZBP-89 predisposes the colon to colitis. Nucleic Acids Res. 2006; 34; 1342-1350.
41. Okada M, Tessier A, Bai L, Merchant JL. P53 mutants suppress ZBP-89 function. Anticancer Res. 2006; 26; 2023-2028.
42. Chen GG, Chan UP, Bai LC et al. ZBP-89 reduces the cell death threshold in hepatocellular carcinoma cells by increasing caspase-6 and S phase cell cycle arrest. Cancer Lett. 2009; 283; 52-58.